Diabetes Archives - Rheumatology Advisor

ACR Convergence 2020

Comparative Performances of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Gout in Type 2 Diabetes

By

Rheumatology Advisor Contributing Writer

November 8, 2020

Researchers compared the beneficial effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on gout risk in patients with type 2 diabetes.

Osteoarthritis

Severe Periodontitis Linked to Osteoarthritis in Middle-Aged and Older Adults With Type 2 Diabetes

By

Sheila Jacobs

November 2, 2020

Researchers determined the association between severity of periodontitis and osteoarthritis in middle-aged and older adults with type 2 diabetes.

Rheumatoid Arthritis

Rheumatoid Arthritis Linked to Higher Risk for Type 2 Diabetes

October 1, 2020

Rheumatoid arthritis is associated with an increased risk for diabetes mellitus incidence.

ASBMR 2020

Type 2 Diabetes Has Detrimental Effects on Trabecular Bone Quality in Osteoporosis

By

Amit Akirov, MD

September 11, 2020

Researchers evaluated and compared trabecular bone quality in patients with osteoporosis with and without type 2 diabetes.

Osteoporosis

Risk for Fractures Unaffected by SGLT2 Inhibitor Use in Type 2 Diabetes

By

Jessica Nye, PhD

September 1, 2020

The use of sodium-glucose transporter-2 inhibitors combined with metformin did not affect fracture risk in T2D.

Gout

Urate-Lowering Therapy May Reduce Type 2 Diabetes Risk in Patients With Gout

By

Emily Pond

August 31, 2020

Researchers investigated the association between gout, urate-lowering therapy use, and the risk of developing type 2 diabetes.

Osteoporosis

Type 2 Diabetes May Negatively Affect Bone Density in Youth

August 31, 2020

Type 2 diabetes may negatively impact bone density around the age of peak bone mass.

Rheumatoid Arthritis

Rheumatoid Arthritis Linked to Lower Risk for Incident Type 2 Diabetes

August 12, 2020

Compared with populations without rheumatoid arthritis, RA is associated with a lower risk for type 2 diabetes mellitus.

General Rheumatology

Considerations for Hydroxychloroquine Use in Patients With Diabetes

By

Morgan E. Meissner

May 29, 2020

Careful consideration should be taken before using hydroxychloroquine in patients with diabetes, particularly in the context of COVID-19.

$In patients with HIV, the disease process and ART may contribute to bone loss, resulting in osteopenia or osteoporosis and increased fracture risk.3,10 Proinflammatory cytokines and viral load contribute directly to reduced bone mineral density through their effects on osteoclast and osteoblast activity, inhibiting new bone formation and accelerating bone loss.3 Other risk factors for bone loss or fracture in the HIV population include low body mass index, smoking, substance abuse, glucocorticoid therapy, hypogonadism, coinfection with hepatitis B virus or hepatitis C virus, and vitamin D deficiency (affects ~90% of patients).3,11 Bone loss caused by ART emerges within 1 to 2 years after starting therapy.3,11 Tenofovir-based regimens are associated with higher rates of bone loss.3,11 Guidelines suggest avoiding tenofovir disoproxil fumarate or PI-boosting regimens in patients at high risk.3 Bisphosphonates (eg, alendronate or zoledronate) are recommended for those with HIV who have osteoporosis.3$

Osteoporosis

Bone Health Declining in Adults With and Without Prediabetes in the United States

May 19, 2020

The bone health of adults older than 40 years of age is declining for individuals both with normal glucose regulation and prediabetes.